Related Experiment Videos
[Risk of thromboembolism and arteriosclerosis in women]
1Medizinische Klinik und Poliklinik C Universitätsklinikum 48129 Münster, Germany. nikol@uni-muenster.de
Insights
Young women face higher risks of venous thromboembolism, influenced by factors like oral contraceptives and smoking. Estrogen impacts cardiovascular health differently in women, necessitating further research into tailored therapies.
Area of Science:
- Cardiovascular Science
- Hematology
- Endocrinology
Context:
- Young women exhibit a threefold higher risk of venous thromboembolism (VTE) than young men.
- Risk factors for VTE in women include oral contraceptives, smoking, thrombophilia, and socioeconomic status.
- Gender-specific differences exist in arterial disease, with coronary heart disease developing later but often with a more complex clinical course in women.
Purpose:
- To explore gender-specific differences in venous and arterial thromboembolism.
- To examine the influence of estrogen on hemostasis, endothelial function, and atherogenesis.
- To highlight the need for sex-specific research in cardiovascular and thromboembolic disease therapies.
Summary:
- Estrogen exerts dual effects: favorable on atherogenesis and endothelial function (via NO release), but unfavorable on hemostasis, leading to hypercoagulability.
- Thrombus formation is influenced by Virchow's triad, with estrogen modulating these elements differently between sexes.
- Non-selective hormone replacement therapy may increase thrombogenicity, suggesting selective estrogen receptor modulators as a potential alternative.
Impact:
- Findings underscore the importance of considering gender in VTE risk assessment and management.
- Highlights potential risks of non-selective hormone therapies and points towards more targeted treatments.
- Emphasizes the critical need for clinical trials in diverse populations, addressing the historical male-predominant research bias.
Abstract:
Young women are at a 3-fold higher risk of experiencing venous thromboembolism compared to young men. This risk is further increased by oral contraceptives, smoking, hereditary thrombophilia and/or low socioeconomic status. There are also hints for gender-specific differences in the arterial system. Coronary heart disease which is particularly important, develops in women 10-15 years later than in men. However, the clinical course in women is often more complicated. In women, thrombophilic predispositions play a more important role before menopause and metabolic risk factors after menopause compared to men. Thrombus formation needs to be initiated by disturbances of at least one element of the Virchow trias. There is principally no difference between men and women. However, all three elements are influenced by estrogen, resulting in gender-specific differences. There is a favorable influence on blood flow by the inhibition of atherogenesis and on the endothelial function by increased NO release, and the unfavorable influence on hemostasis resulting in hypercoagibility. Thus, particularly non-selective hormone replacement therapy for the inhibition of atherogenesis may be questionable due to increased thrombogenicity. The solution may be more selective estrogen receptor modulators. Clinical trials are still needed for both hormone replacement therapy and the therapy of venous and arterial thromboembolism, which have been studied in predominantly male patient cohorts so far.